908 Devices (MASS) Debt to Equity (2020 - 2026)

Name: 908 Devices (MASS) Debt to Equity (2020 - 2026) | Business Quant
Creator: Business Quant

908 Devices (MASS) reported Debt to Equity of $0.17 for Q1 2026, up 49.75% on a QoQ basis from $0.11 in Q4 2025.

908 Devices (MASS) has 6 years of Debt to Equity data on file, last reported at $0.17 in Q1 2026.

Quarterly Debt to Equity changed N/A year-over-year to $0.17 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.17 (changed N/A YoY) and the FY2025 annual result came in at $0.11, changed N/A from the prior year.
Debt to Equity grew to $0.17 in Q1 2026 per MASS's latest filing, from $0.11 in the prior quarter.
Across five years, Debt to Equity topped out at $0.17 in Q3 2025 and bottomed at $0.0 in Q4 2023.
The 4-year median for Debt to Equity is $0.08 (2022), against an average of $0.07.
The widest annual swing landed in 2022, when Debt to Equity grew 21.92%; it then tumbled 96.45% in 2023.
Tracing MASS's Debt to Equity over 4 years: stood at $0.09 in 2022, then plunged by 96.45% to $0.0 in 2023, then surged by 3591.04% to $0.11 in 2025, then jumped by 49.75% to $0.17 in 2026.
Per Business Quant, the three latest MASS Debt to Equity figures stand at $0.17 (Q1 2026), $0.11 (Q4 2025), and $0.17 (Q3 2025).

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn	0.65
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn	0.64
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn	0.57
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn	0.95
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn	0.27
10	908 Devices	314.43 Mn	202.69 Mn	6.88 Mn	0.17

Download Data 🔒